A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors
- 3 August 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 30 (4), 1566-1574
- https://doi.org/10.1007/s10637-011-9725-2
Abstract
Because cancer patients may have difficulty swallowing whole tablets, crushing tablets or ingesting an oral suspension is a practical alternative. This open-label, 2-part, randomized crossover, phase I study evaluated the pharmacokinetics and tolerability of pazopanib administered as a crushed tablet or an oral suspension relative to whole tablet in patients with advanced cancer (Part 1). Patients completing Part 1 were eligible for continuous daily pazopanib 800 mg (Part 2). Administration of a single pazopanib 400 mg crushed tablet increased the area under the curve from 0 to 72 h (AUC(0–72); 46%) and maximum observed plasma concentration (Cmax; ~2-fold), and decreased time to achieve maximum plasma concentration (Tmax; ~2 h), indicating increased rate and extent of oral absorption relative to whole-tablet administration. Similarly, a single dose of pazopanib 400 mg suspension increased AUC(0–72) (33%) and Cmax (29%), and decreased Tmax (1 h). These changes in pharmacokinetic parameters were not associated with increases in the magnitude or duration of short-term (ie, up to 72 h) blood pressure elevation compared with whole-tablet administration.Keywords
This publication has 14 references indexed in Scilit:
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancerGynecologic Oncology, 2010
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyThe Lancet Oncology, 2010
- Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2010
- Phase I Trial of Pazopanib in Patients with Advanced CancerClinical Cancer Research, 2009
- Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II studyJournal of Clinical Oncology, 2008
- Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activityMolecular Cancer Therapeutics, 2007
- Pazopanib: A novel multitargeted tyrosine kinase inhibitorCurrent Oncology Reports, 2007
- AngiogenesisAnnual Review of Medicine, 2006
- Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and TherapyJournal of Clinical Oncology, 2002
- Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors.Molecular Biology of the Cell, 1992